On Friday, Mersana Therapeutics Inc (NASDAQ: MRSN) was -12.30% drop from the session before settling in for the closing price of $2.52. A 52-week range for MRSN has been $1.22 – $6.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 12371.94% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 59.53%. With a float of $90.69 million, this company’s outstanding shares have now reached $120.71 million.
In an organization with 123 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 48.0%, operating margin of -228.07%, and the pretax margin is -212.99%.
Mersana Therapeutics Inc (MRSN) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Mersana Therapeutics Inc stocks. The insider ownership of Mersana Therapeutics Inc is 26.59%, while institutional ownership is 66.05%. The most recent insider transaction that took place on Oct 28 ’24, was worth 3,580. In this transaction SVP, Chief Development Officer of this company sold 1,884 shares at a rate of $1.90, taking the stock ownership to the 54,731 shares. Before that another transaction happened on Oct 28 ’24, when Company’s Officer proposed sale 1,884 for $2.04, making the entire transaction worth $3,843.
Mersana Therapeutics Inc (MRSN) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.16 earnings per share (EPS) during the time that was better than consensus figure (set at -0.19) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.53% per share during the next fiscal year.
Mersana Therapeutics Inc (NASDAQ: MRSN) Trading Performance Indicators
You can see what Mersana Therapeutics Inc (MRSN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.63 in one year’s time.
Technical Analysis of Mersana Therapeutics Inc (MRSN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.56 million. That was inferior than the volume of 1.61 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 63.43%. Additionally, its Average True Range was 0.24.
During the past 100 days, Mersana Therapeutics Inc’s (MRSN) raw stochastic average was set at 61.49%, which indicates a significant increase from 39.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 143.02% in the past 14 days, which was higher than the 100.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.03, while its 200-day Moving Average is $2.72. However, in the short run, Mersana Therapeutics Inc’s stock first resistance to watch stands at $2.48. Second resistance stands at $2.75. The third major resistance level sits at $2.88. If the price goes on to break the first support level at $2.07, it is likely to go to the next support level at $1.94. The third support level lies at $1.67 if the price breaches the second support level.
Mersana Therapeutics Inc (NASDAQ: MRSN) Key Stats
There are 123,533K outstanding shares of the company, which has a market capitalization of 239.43 million. As of now, sales total 36,860 K while income totals -171,670 K. Its latest quarter income was 2,290 K while its last quarter net income were -24,270 K.
